Der Diabetologe

, Volume 8, Issue 5, pp 377–385

Typ-1-Diabetes

Topics 2011
Leitthema
  • 315 Downloads

Zusammenfassung

Im Jahr 2011 und Anfang 2012 wurde eine Reihe hoch interessanter Beiträge zum Thema Typ-1-Diabetes veröffentlicht. In der vorliegenden Übersicht werden „Top-Publikationen“ aus den Bereichen Epidemiologie, Prävention, Insulintherapie, Insulinpumpentherapie, sensorunterstützte Pumpentherapie (SUP) und neue Therapieoptionen vorgestellt. Die hohe Zahl wegweisender Publikationen war in den Themenbereichen Prävention und SUP auffällig. Zum Thema Prävention wurden überwiegend Arbeiten auf dem Gebiet der Tertiärprävention publiziert. Die Ergebnisse zeigten keine Heilung, jedoch häufig eine Progressionshemmung. Die Publikationen im Bereich der SUP belegen die Überlegenheit dieser Therapieform im Vergleich zur klassischen intensivierten konventionellen Insulintherapie (ICT) bzw. Pumpentherapie ohne Sensor, wenn der Sensor möglichst häufig getragen wird. Die Gesamtheit der vorliegenden Studien deutet darauf hin, dass sich diese Therapieform zum neuen Goldstandard bei Typ-1-Diabetes entwickeln kann.

Schlüsselwörter

HbA1c Insulin Autoantikörper Infusionspumpen Monitoring 

Type 1 diabetes

Topics 2011

Abstract

In 2011 and the beginning of 2012 several exciting papers in the field of type 1 diabetes were published. This review selects the top publications in the fields of epidemiology, prevention, insulin therapy, insulin pump therapy, sensor-augmented pump therapy and new therapeutic options. Especially in the areas of type 1 diabetes prevention and sensor-augmented pump therapy, 2011 was a year with groundbreaking publications. Most papers in the prevention field were published on tertiary prevention projects. The results revealed a slowing down of disease progression but not healing of the disease. Publications in the field of sensor-augmented pump therapy showed superiority compared to multiple daily injections or classic pump therapy in cases where the sensor wear times were high. The currently available studies indicate that sensor-augmented pump therapy could be the future gold standard therapy for patients with type 1 diabetes.

Keywords

HbA1c Insulin Autoantibodies Infusion pumps Monitoring 

Literatur

  1. 1.
    Błazik M, Pańkowska E (2012) The effect of bolus and food calculator Diabetics on glucose variability in children with type 1 diabetes treated with insulin pump: the results of RCT. Pediatr Diabetes. DOI 10.1111/j.1399-5448.2012.00876.xGoogle Scholar
  2. 2.
    Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300PubMedCrossRefGoogle Scholar
  3. 3.
    Bergenstal RM, Tamborlane WV, Ahmann A et al (2010) Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363:311–320PubMedCrossRefGoogle Scholar
  4. 4.
    Bergenstal RM, Tamborlane WV, Ahmann A et al (2011) Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 34:2403–2405PubMedCrossRefGoogle Scholar
  5. 5.
    Buzzetti R, Cernea S, Petrone A et al (2011) C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 60:3067–3072PubMedCrossRefGoogle Scholar
  6. 6.
    Danne T, Kordonouri O, Holder M et al (2011) Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 13:1129–1134PubMedCrossRefGoogle Scholar
  7. 7.
    Deiss D, Bolinder J, Riveline JP et al (2006) Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 29:2730–2732PubMedCrossRefGoogle Scholar
  8. 8.
    Ehehalt S, Dietz K, Willasch AM, Neu A; for the DIARY-Group Baden-Wuerttemberg (2011) Prediction model for the incidence and prevalence of type 1 diabetes in childhood and adolescence: evidence for a cohort-dependent increase within the next two decades in Germany. Pediatr Diabetes 13:15–20PubMedCrossRefGoogle Scholar
  9. 9.
    Ellis SL, Moser EG, Snell-Bergeon JK et al (2011) Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 28:1176–1181PubMedCrossRefGoogle Scholar
  10. 10.
    Fourlanos S, Perry C, Gellert SA et al (2011) Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60:1237–1245PubMedCrossRefGoogle Scholar
  11. 11.
    Hummel S, Pflüger M, Hummel M et al (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301–1305PubMedCrossRefGoogle Scholar
  12. 12.
    Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 33:17–22CrossRefGoogle Scholar
  13. 13.
    Kielgast U, Krarup T, Holst JJ, Madsbad S (2011) Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 34:1463–1468PubMedCrossRefGoogle Scholar
  14. 14.
    Ludvigsson J, Krisky D, Casas R et al (2012) GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366:433–442PubMedCrossRefGoogle Scholar
  15. 15.
    Mastrototaro J, Shin J, Marcus A et al (2008) The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther 10:385–390PubMedCrossRefGoogle Scholar
  16. 16.
    McQueen RB, Ellis SL, Campbell JD et al (2011) Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc 9:13PubMedCrossRefGoogle Scholar
  17. 17.
    Michels AW, Herrath M von (2011) 2011 Update: antigen-specific therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 18:235–240PubMedCrossRefGoogle Scholar
  18. 18.
    Murphy HR, Elleri D, Allen JM et al (2011) Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 4:406–411CrossRefGoogle Scholar
  19. 19.
    Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378:412–419PubMedCrossRefGoogle Scholar
  20. 20.
    Pańkowska E, Błazik M, Groele L (2012) Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther 14:16–22PubMedCrossRefGoogle Scholar
  21. 21.
    Patterson CC, Dahlquist GG, Gyürüs E et al (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–2020: a multicentre prospective registration study. Lancet 373:2027–2033PubMedCrossRefGoogle Scholar
  22. 22.
    Pickup JC, Freeman SC, Sutton AJ (2011) Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 343:d3805PubMedCrossRefGoogle Scholar
  23. 23.
    Raccah D, Sulmont V, Reznik Y et al (2009) Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Care 32:2245–2250Google Scholar
  24. 24.
    Siegmund T, Kolassa R, Thomas A (2011) Sensorunterstützte Therapie (SuT) und Sensorunterstützte Pumpentherapie (SuP), 1 Aufl. UNI-MED Science, Bremen, ISBN 978-3-8374-1232-1Google Scholar
  25. 25.
    Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487–497PubMedCrossRefGoogle Scholar
  26. 26.
    Simon AC, DeVries JH (2011) The future of basal insulin supplementation. Diabetes Technol Ther 13(Suppl 1):103–108CrossRefGoogle Scholar
  27. 27.
    Vehik K, Cuthbertson D, Ruhlig H et al (2011) Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 34:1585–1590PubMedCrossRefGoogle Scholar
  28. 28.
    Yu L, Herold K, Krause-Steinrauf H et al (2011) Rituximab selectively suppresses specific islet antibodies. Diabetes 60:2560–2565PubMedCrossRefGoogle Scholar
  29. 29.
    Patterson CC, Dahlquist GG, Gyürüs E et al (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989–2003. Lancet 373:2027–2033PubMedCrossRefGoogle Scholar
  30. 30.
    Bergenstal RM, Tamborlane WV, Ahmann A et al (2011) Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 34:2403–2405PubMedCrossRefGoogle Scholar
  31. 31.
    Murphy HR, Elleri D, Allen JM et al (2011) Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 34:406–411PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Klinik für Endokrinologie, Diabetologie und AngiologieStädt. Klinikum München GmbH, Klinikum BogenhausenMünchenDeutschland

Personalised recommendations